How much atrial fibrillation causes symptoms of heart failure?
|
|
- Primrose Watson
- 6 years ago
- Views:
Transcription
1 ORIGINAL PAPER How much atrial fibrillation causes symptoms of heart failure? M. Guglin, R. Chen Linked Comment: Lip. Int J Clin Pract 2014; 68: SUMMARY Introduction: Patients with atrial fibrillation (AF) are more symptomatic than patients with sinus rhythm. However, it is unknown what per cent of time spent in AF is associated with symptoms. Methods: We used a limited access dataset from the Atrial Fibrillation Follow-up Investigation of Rhythm Management trial. Patients had their current rhythm and New York Heart Association (NYHA) class recorded at baseline and at every follow-up visit. The ratio of number of visits when patients were in AF to the total number of visits was used as a surrogate measure of AF burden. The median number of visits was 12 per patient. We grouped patients labelled as class 0 and I by NYHA as having no symptoms and NYHA II or III as having symptoms. Furthermore, we calculated mortality and the prevalence of symptoms depending on the per cent of visits when they had AF. Results: Of 4060 patients enrolled in the trial, 74 had no follow-up visits and were excluded; the remaining 3986 patients were analysed. Patients who had no or little AF throughout the study (0 20%) had the lowest prevalence of symptoms. Prevalence of symptoms increased with greater per cent of time spent in AF. Specifically, symptoms became more prevalent when AF burden reached 20 40%. Mortality was similar regardless of proportion of visits when patients were in AF. Conclusions: Higher AF burden is associated with higher prevalence of symptoms. The increment became significant when patients were in AF at 20 40% of visits. What s known Atrial fibrillation (AF) is associated with more symptoms and poorer exercise tolerance than sinus rhythm. Many symptoms of AF are related to heart failure (HF). What s new It is unknown how much time does the patient need to be in AF to start experiencing symptoms of HF. We demonstrated, for the first time, that symptomatic deterioration in AF starts with 20 40% of time spent in AF. University of South Florida, Tampa, FL, USA Correspondence to: Maya Guglin, University of South Florida, Tampa, FL, USA Tel.: Fax: mguglin@gmail.com Disclosure We do not have any conflicts of interest. Introduction Studying the data from the Atrial Fibrillation Followup Investigation of Rhythm Management (AFFIRM) trial, Chung et al. (1) clearly demonstrated that presence of AF was associated with worse functional class, regardless of the treatment arm. In our previous study, we found that symptomatic heart failure (HF) was more common in the rate control than in the rhythm control arm. Unlike prior analyses, we pooled patients without HF symptoms (NYHA, New York Heart Association 0 and I) and with symptomatic HF (NYHA II and III), and based the comparison on the number of follow-up visits when patients current rhythm and NYHA functional class were recorded (2). New York Heart Association includes dyspnoea, fatigue and palpitations, graded by the amount of physical activity producing them. In the context of AF, these symptoms may manifest HF, but not necessarily, because symptoms may be experienced because of AF itself. It remains unknown whether the total amount of time spent in AF is associated with worse symptoms, and if it is, then the question remains, of how much time spent in AF results in more severe symptoms. Our objective was to compare the prevalence of symptoms defined as NYHA II/III depending on the per cent of time spent in AF. Methods We used a limited access dataset from the AFFIRM trial provided by the National Heart, Lung and Blood Institute. This study enrolled 4060 patients with AF who required long-term therapy and who were 65 years of age or older or who had other risk factors for stroke or death (3). Patients current rhythm and NYHA functional class were recorded at baseline and at every follow-up visit. The ratio of number of visits when patients were in AF to the total number of visits (including baseline) was used as a surrogate measure of AF burden. Patients were divided into five groups based on the ratio of visits. doi: /ijcp
2 454 Atrial fibrillation and heart failure they appeared to be in AF to the total number of visits: 0 20%, 21 40%, 41 60%, 61 80% and %. Treatment arm (rate control or rhythm control) was not taken into account. In the trial, patients were classified by the investigators as NYHA functional class 0, I, II and III. There were no patients in NYHA class IV. Because the difference between NYHA 0 and NYHA I is not clear, we grouped patients labelled as class 0 and I by NYHA as having no symptoms and NYHA II or III as having symptoms. For each patient, per cent of follow-up visits when they were in AF ( AF burden ) was calculated. We compared the baseline characteristics of patients based on the per cent of visits they had AF. Symptoms defined as being in NYHA II III class, general mortality, cardiovascular mortality and non-cardiovascular mortality were compared depending on AF burden. Outcomes were adjusted for the baseline differences in the multivariate analysis with linear regression. As over 70% of patients did not have symptoms on any of the follow-up visits, the event of having symptoms was assumed to follow a Poisson distribution. To check the five AF burden categories, a generalised mixed linear model was applied. All statistics was conducted using SAS (version 9.2; SAS, Cary, NC, USA). Results Of 4060 patients enrolled in the trial, 74 had no follow-up visits and were excluded; therefore, a dataset of the remaining 3986 patients was analysed. Mean age was years, and 60.8% were male. Throughout the study, the median number of visits per patient was 12 (range 2 18). The per cent of visits when the patients were in AF was as following: 1871 (46.9%) patients had no or little AF throughout the study (0 20% of visits), 476 (11.9%) had AF on 21 40% of visits, 343 (8.6%) had AF on 41 60% of visits, 346 (8.7%) had AF on 61 80% of visits and 950 (23.8%) had AF on more than 80% of visits. Baseline characteristics of these five groups are detailed in Table 1. The groups differed in gender, diastolic blood pressure which was lower in patients with lowest prevalence of AF, and, as expected, in prevalence of history of HF. Patients who had no or little AF throughout the study (0 20% of visits) had the lowest prevalence of symptoms (7.7%). This group was used as a reference for the other groups with higher prevalence of AF. All groups of patients with greater AF burden had significantly higher prevalence of symptoms (Tables 2 and 3). Thus, 10% of patients who were in AF on 21 40% of follow-up visits had NYHA II III symptoms (odds ratio 1.3, 95% confidence intervals , p = 0.02). This number further increased in those who presented in AF at 40 60% of visits (12.7%, odds ratio 1.75, 95% confidence intervals , p < ). Maximal prevalence of symptoms was observed in patients with an AF burden 61 80% (13.7%, odds ratio 1.9, 95% confidence intervals , p < 0.001). Prevalence of NYHA Table 1 Baseline characteristics of patients based on the per cent of visits they were in AF Percentage of visits when patients were in AF Overall 0 20% 21 40% 41 60% 61 80% % p-value (46.9%) 476 (11.9%) 343 (8.6%) 346 (8.7%) 950 (23.8%) Continuous variables, mean SD Age Systolic blood pressure (mmhg) Diastolic blood pressure (mmhg) < Body mass index (kg/m 2 ) Categorical variables, n (%) Gender: male 2423 (60.8) 57.2% 65.8% 56.9% 63.9% 65.6% < History of coronary artery disease 1522 (32.8) 38.1% 40.3% 39.1% 43.4% 35.2% History of congestive heart failure 913 (22.9) 20.5% 24.0% 27.1% 26.3% 24.4% History of diabetes 798 (20.0) 20.2% 20.0% 20.4% 25.1% 17.7% History of hypertension 2830 (71.0) 71.5% 68.9% 72.0% 69.7% 71.2% History of myocardial infarction 692 (17.4) 17.2% 18.3% 16.3% 19.1% 17.0% History of stroke 527 (13.2) 12.9% 13.5% 13.4% 15.0% 13.0% Smoking 11.8% 13.7% 15.2% 11.3% 11.4% Rhythm at time of randomisation Atrial fibrillation or flutter % 55.0% 46.7% 47.0% 76.4% < Sinus % 45.0% 53.3% 53.0% 23.6%
3 Atrial fibrillation and heart failure 455 Table 2 Prevalence of symptoms and mortality depending on AF burden AF burden 0 20% 21 40% 41 60% 61 80% % Total n of patients Symptomatic HF (NYHA II-III), n (%) 144 (7.7) 48 (10.1)* 43 (12.7)* 46 (13.7)* 106 (11.2)* Cardiovascular death, n (%) 124 (6.6) 37 (7.1) 29 (8.5) 22 (6.4) 88 (9.3) Non-cardiac, n (%) 142 (7.6) 34 (7.1) 23 (6.7) 21 (6.1) 53 (5.6) Unknown reason of death, n (%) 15 (0.8) 6 (1.3) 5 (1.5) 7 (2) 15 (1.6) Any death, n (%) 281 (15) 77 (16.2) 57 (16.6) 50 (14.5) 156 (16.4) Symptomatic NYHA classes were significantly more prevalent in the subgroups with higher AF burden, Mortality was not different. AF, atrial fibrillation; HF, heart failure; NYHA, New York Heart Association. *Difference from 0% to 20% group is statistically significant. For details, see Table 3. Table 3 Comparison of prevalence of symptoms between the groups with different prevalence of AF AF burden (%) Odds ratio Standard error Wald 95% Confidence limits p 0 20 Reference < < < AF, atrial fibrillation. II III symptoms in patients with AF burden of 41 60% and in those who spent almost all of the time in AF (81 100%) was similar (12.7% and 11.2%, respectively). There was no difference in cardiac, non-cardiac or total mortality depending on per cent of visits when the patients were in AF (Table 2). In multivariate analysis, with gender, diastolic blood pressure and history of HF entered into the model, per cent of visits when patients were in AF was strongly associated with NYHA II/III symptoms (p < ). Discussion In this retrospective analysis of the AFFIRM limited access dataset, we demonstrated that the least amount of time spent in AF (0 20%) was associated with the most favourable profile in terms of symptoms. Patients who appeared to be in AF on more than 20% of follow-up visits had an increasingly higher prevalence of NYHA II III symptoms. The maximal prevalence of symptoms was observed in patients who spent 61 80% of time in AF. Their risk of having symptoms was almost double (odds ratio 1.9) compared with the lowest risk group. Furthermore, prevalence of NYHA II III symptoms was somewhat lower in those who remained in AF almost all time (81 100%). For this group, the risk of having symptoms was 11.2%, or 1.5 times higher than in those with minimal AF burden group. Because the patients in the AFFIRM trial did not have implantable devices which would accurately record the amount of time spent in AF (true AF burden), we used per cent of visits when patients appeared to be in AF as a surrogate. The number of visits per patients in the AFFIRM trial was quite high, with the median of 12. Fully realising the crudeness of such estimate, we still think it is logical to assume that if somebody had documented AF at 8 of 12 visits, their AF burden was higher than in those who only had AF at the baseline and sinus rhythm at each subsequent visit. The argument about advantages and disadvantages of being in AF is ongoing. It was addressed in two large randomised controlled clinical trials AFFIRM (3) and RACE (4) and multiple publications thereafter. As was demonstrated in both trials, AF is not associated with greater morbidity or mortality than is sinus rhythm. To our knowledge, stratification of these data by AF burden was never conducted before. In this study, cardiac, non-cardiac or total mortality
4 456 Atrial fibrillation and heart failure was the same regardless of the amount of time patients spent in AF. The Atrial Fibrillation and Congestive Heart Failure trial, which specifically addressed the question on AF in patients with HF secondary to left ventricular systolic dysfunction, also showed that a routine strategy of rhythm control does not reduce the cardiovascular mortality more than a rate control strategy (5). The question about functional status, or symptoms, is more controversial. According to a subanalysis of the AFFIRM, functional status was similar in patients with different degrees of left ventricular systolic dysfunction, whether they were randomised into a rate control or rhythm control arm (6). In addition, in the RACE trial, rate control was not inferior to rhythm control in mild to moderate HF; however, the conclusion was made that, if sinus rhythm could be maintained, outcomes might improve (7). When patients of the AFFIRM were analysed by their actual rhythm, rather than by their arm, it appeared that functional status was better when they were in sinus rhythm, regardless of the treatment strategy as well as of the time elapsing from the beginning of the study, but the amount of AF needed to produce symptoms was not estimated (1). In our prior study (2), we demonstrated for the first time that, in the AFFIRM trial, symptomatic HF was more common in the rate control than in the rhythm control arm. HF was not an inclusion criterion to the AFFIRM trial and was present in a minority of patients. In fact, 90% of all individuals enrolled in the trial had NYHA class 0 or I symptoms. To overcome this limitation, we pooled patients without HF symptoms (NYHA 0 and I) and those with symptomatic HF (NYHA II and III). In an analysis based on actual rhythm, we also found that NYHA functional status was best in patients who were in stable sinus rhythm, was somewhat worse if they were consistently in AF, and much worse if they switched between rhythm control and rate control strategies. Furthermore, patients had fewer symptoms and required fewer medications, such as angiotensin converting enzyme inhibitors and diuretics, when they were in sinus rhythm compared with AF (2). There are many data available regarding the disadvantages of being in AF. For example, AF is associated with an increased total and HF mortality (8) and with a 2.5 times higher likelihood of being in NYHA class III IV vs. I II, even after adjustment for age, left ventricular ejection fraction and aetiology of HF. In additionally, patients with similar functional class and left ventricular ejection fraction have higher BNP (9), shorter 6-min walking distance, poorer quality of life, more severe diastolic dysfunction and more frequent hospitalisations for HF if they also had AF (10). Conversely, being in a normal sinus rhythm was linked to improved survival in the DIAMOND study (11). In an on-treatment analysis of the AFFIRM study, sinus rhythm was also associated with mortality reduction (12). Restoration and maintenance of sinus rhythm for 3 months resulted in improved systolic function (13) and long-term prognosis (14). Similar effects of sinus rhythm on left ventricular ejection fraction and decrease in left atrial size was observed in a subanalysis of the RACE trial (15). When patients with persistent AF and chronic symptomatic HF were randomised to rhythm or rate control, 1 year later, left ventricular systolic function and NT-proBNP levels were better in the rhythm control arm (16). Despite the above observations, the question of quantity of AF translating into worse functional status or symptoms on exertion has not previously been investigated. Intuitively, it seems that more AF would result in worse symptoms; this was true on a comparison of AF burden of 0 20%, 21 40%, 41 60% and 61 80%. The prevalence of symptomatic classes of HF, NYHA II and III, increased from 7.7% to 10.1%, 12.7% and 13.7%, respectively. However, in the group with the highest AF burden, %, there was a decrease in prevalence of symptomatic HF to 11.2%. In our prior analysis of the AFFIRM, we found something very similar. Specifically, the highest NYHA functional class was not found among patients with stable AF but in patients who changed treatment arms back and forth several times. It appears that stable chronic AF may be better tolerated than is intermittent AF with some amount of time spent in sinus rhythm. Although the number of follow-up visits when the patients were in AF is a crude surrogate for AF burden, NYHA class is a surrogate for symptoms. Exertional dyspnoea or fatigue are quite non-specific and can be a manifestation of HF or AF per se. History of HF was less prevalent in patients with the lowest AF burden, but as the tools, used to establish such a history, were not specified, this finding is very difficult to interpret. Patients in this category could have been less symptomatic before the study because of lower prevalence of HF or because of lower AF burden. Limitations We only analysed the data available from the limited access dataset of the AFFIRM and did not have access to the complete study data. In addition, this was a retrospective analysis of the main trial;
5 Atrial fibrillation and heart failure 457 therefore, the results should be interpreted with caution. Per cent of clinic visits, when patients were in AF, was used as a surrogate of AF burden. Throughout the text, when we say that AF burden was, for example, 40%, it only means that when the patient came to follow-up visit they were in AF 40% of the visits. Because none of the patients were under continuous monitoring, it is impossible to say what rhythm they were in between the visits. Conclusions Higher AF burden is associated with higher prevalence of symptoms. This increment becomes significant at the level of AF burden of 21 40% and increases progressively until it reached a level of 61 80%. Patients in chronic AF, with a burden %, demonstrated fewer symptoms than those with less prevalent AF. Acknowledgement The Atrial Fibrillation Follow-up Investigation of Rhythm Management is conducted and supported by the NHLBI in collaboration with the AFFIRM Study Investigators. This manuscript was prepared using a limited access dataset obtained from the NHLBI and does not necessarily reflect the opinions or views of the AFFIRM or the NHLBI. Authorship Maya Guglin study hypothesis, study design, IRB submission, obtaining an agreement with NHLBI, initial statistics, drafting and editing the manuscript. Ren Chen data analysis. Maya Guglin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. References 1 Chung MK, Shemanski L, Sherman DG et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005; 46: Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm 2010; 7: Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol 2007; 100: Hagens VE, Crijns HJ, Van Veldhuisen DJ et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005; 149: Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: Corell P, Gustafsson F, Kistorp C et al. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 2007; 117: Fung JW, Sanderson JE, Yip GW et al. Impact of atrial fibrillation in heart failure with normal ejection fraction: a clinical and echocardiographic study. J Card Fail 2007; 13: Pedersen OD, Bagger H, Keller N et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104: Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: Grubitzsch H, Dushe S, Beholz S et al. Surgical ablation of atrial fibrillation in patients with congestive heart failure. J Card Fail 2007; 13: Friberg L, Hammar N, Edvardsson N, Rosenqvist M. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored report from the Stockholm Cohort of Atrial Fibrillation (SCAF). Heart 2009; 95: Hagens VE, Van Veldhuisen DJ, Kamp O et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005; 2: Shelton RJ, Clark AL, Goode K et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II study). Heart 2009; 95: Paper received April 2013, accepted July 2013
Atrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationJournal of the American College of Cardiology Vol. 43, No. 2, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 43, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.08.037
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationNitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial
Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial Margaret M Redfield On behalf of the NHLBI Heart Failure Clinical Research Network
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationDoes quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?
Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)? Erika Friedmann a, Eleanor Schron, b Sue A. Thomas a a University of Maryland School of Nursing; b NEI, National
More informationReviews. Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation
Reviews Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation Address for correspondence: Stefan H. Hohnloser, MD Department of Cardiology J.W. Goethe University Hospital
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationTitle:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis
Author's response to reviews Title:Relation Between E/e' ratio and NT-proBNP Levels in Elderly Patients with Symptomatic Severe Aortic Stenosis Authors: Mihai Strachinaru (m.strachinaru@erasmusmc.nl) Bas
More informationTreatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide?
Treatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide? Uta C. Hoppe Dep. of Internal Medicine III University of Cologne No conflict of interest
More informationRole of Dronedarone in Atrial Fibrillation: More Questions Than Answers
Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers Daniel E. Hilleman, Pharm.D., FCCP, and Aryan N. Mooss, M.D. Key Words: dronedarone, atrial fibrillation, sinus rhythm, hypertension,
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationCatheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?
: Another Option for AF Atrial fibrillation (AF) is a highly common cardiac arrhythmia and a major risk factor for stroke. In this article, Dr. Khan and Dr. Skanes detail how catheter ablation significantly
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationThe Atrial Fibrillation Follow-up Investigation of Rhythm
Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study The AFFIRM Investigators* Background The AFFIRM Study
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationSetting The setting was secondary care. The economic study was carried out in the USA and Canada.
Cost-effectiveness of rhythm versus rate control in atrial fibrillation Marshall D A, Levy A R, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene H L, Wyse D G, Nichol G, O'Brien B J Record Status This
More information* Corresponding author. Tel.: ; fax: address: (IsabelleC. Van Gelder).
European Heart Journal (2004) 25, 1542 1549 Clinical research Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation results from the RAte Control versus
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationAbstract nr. 1 Abstract code Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial
Abstract nr. 1 Hybrid Versus Catheter Ablation for Atrial Fibrillation: the HARTCAP-AF Trial Auteur Vroomen, M., Maastricht University Medical Center, Maastricht, Nederland Co-auteur(s) - La Meir, M. Co-auteur(s)
More informationManagement of atrial fibrillation in heart failure
Nationale hartfalendag 2017 Zeist Management of atrial fibrillation in heart failure Isabelle C Van Gelder University of Groningen University Medical Center Groningen The Netherlands Disclosures Grant
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationHeart Failure and Atrial Fibrillation
Heart Failure and Atrial Fibrillation 신미승 가천의대심장내과 Prevalence of AF & CHF AF : the most common cardiac arrhythmia more than 2.2 million Americans -- 2007 ACC CHF : more than 5 million Americans The prevalence
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationAtrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen
Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder The Netherlands Madrid Europace June 2011 Conflict of interests Research grants from Medtronic, SJM, Biotronik, Boston,
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationQuality of Life and Functional Capacity in Patients With Atrial Fibrillation and Congestive Heart Failure
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.031
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationEfficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function
Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationTechnology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267
Ivabradine adine for treating chronic heart failure Technology appraisal guidance Published: 28 November 2012 nice.org.uk/guidance/ta267 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationJournal of the American College of Cardiology Vol. 46, No. 7, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 7, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.078
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationAdvances in Cardiac Arrhythmias and Great innovations in Cardiology Turin October 2016
University of Brescia School of Medicine Division of cardiologiy Director: Prof Marco Metra, MD, FESC Advances in Cardiac Arrhythmias and Great innovations in Cardiology Turin 13-15 October 2016 Arrhythmias
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationProgression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro
Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA PATTERN
Atrial Fibrillation and Heart Failure: the ugly and the nasty 13 International Meeting February 14-15 th 2019, Bologna ATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationRate vs. Rhythm Control in Atrial Fibrillation
Rate vs. Rhythm Control in Atrial Fibrillation Recent Perspectives Saeed Oraii MD Electrophysiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic Delirium Cordis First described by Sir
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationFibrillazione atriale e scompenso: come interrompere il circolo vizioso.
Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationECTOPIC BEATS: HOW MANY COUNT?
ECTOPIC BEATS: HOW MANY COUNT? Rupert FG Simpson, 1 Jessica Langtree, 2 *Andrew RJ Mitchell 2 1. King s College Hospital, London, UK 2. Jersey General Hospital, Jersey, UK *Correspondence to mail@jerseycardiologist.com
More informationPlanning and monitoring of patients for electrical cardioversion for atrial fibrillation
Neth Heart J (2012) 20:148 154 DOI 10.1007/s12471-011-0208-z ORIGINAL ARTICLE Planning and monitoring of patients for electrical cardioversion for atrial fibrillation J. H. H. Deuling & R. P. Vermeulen
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationThe prevalence of atrial fibrillation (AF), already the most common sustained cardiac arrhythmia,
Electrophysiology ATRIAL FIBRILLATION: CLASSIFICATION, PATHOPHYSIOLOGY, MECHANISMS AND DRUG TREATMENT See end of article for authors affiliations Correspondence to: Dr Vias Markides, Waller Cardiac Department,
More informationCost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H
Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation Chan P S, Vijan S, Morady F, Oral H Record Status This is a critical abstract of an economic evaluation that meets the criteria
More information'Understanding Atrial Fibrillation: New Insights in Pathophysiology
82 nd Annual Scientific Meeting of the Japanese Circulation Society Osaka 2018 'Understanding Atrial Fibrillation: New Insights in Pathophysiology Barbara Casadei, MD DPhil FMedSci FESC British Heart Foundation
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationREVIEW ARTICLE. the most frequently encountered
REVIEW ARTICLE vs Rhythm Control in Patients With Atrial Fibrillation A Meta-analysis Simon de Denus, MSc; Cynthia A. Sanoski, PharmD; Jörg Carlsson, MD; Grzegorz Opolski, MD; Sarah A. Spinler, PharmD
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationBaseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide
DOI 10.1007/s12471-015-0659-8 Design Study Article Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide Ahmad Shoaib Amin René H.J. Peters Maaike Verstraaten
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationCatheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD
Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD Taipei Veterans General Hospital, Taiwan Outline of AF Ablation 1. Strategy for Catheter Ablation of AF 2. Substrate
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationThe REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial David M Kaye
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More information